ADA Standards of Medical Care in Diabetes with Dr. Bob Gabbay

In this episode of Curbside Consults, we examine the latest standards of medical care published by the American Diabetes Association (ADA). We are joined by Dr. Bob Gabbay, who is Chief Science and Medical Officer at the American Diabetes Association, an Associate Professor of Medicine at Harvard Medical School, and one of the authors of the ADA’s new 2022 Standards of Medical Care in Diabetes document.

Articles discussed in this episode:

1. Draznin B et al. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2022. Diabetes Care 2022.
2. Perkovic V et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med 2019.
3. Wiviott SD et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 2019.
4. Pitt B et al. Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes. N Engl J Med 2021.
5. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med 2022.
6. ADA Standards of Care App

The Curbside Consults series complements the foundational information in Rotation Prep by taking a deep dive into key clinical topics with expert clinicians and educators. These podcasts explore and critique the evidence behind clinical practice and break down statistical concepts for the busy clinical trainee.

Bob Gabbay, MD, PhD, FACP, is Chief Scientific and Medical Officer for the American Diabetes Association (ADA), an Associate Professor of Medicine at Harvard Medical School, and one of the authors of the ADA’s new 2022 Standards of Medical Care in Diabetes document.Clement Lee, MD, MSc, is a 2021–2022 NEJM Editorial Fellow. He is currently an internal medicine hospitalist at Beth Israel Deaconess Medical Center and a pediatric hospitalist at Lowell General Hospital. He completed his internal medicine-pediatrics residency at Penn-CHOP.